Mineralocorticoid receptor antagonists (MRAs), the oldest of which—spironolactone—has been known for over 60 years [15], are associated with a significant reduction in the risk of cardiovascular events [16,17], and effective treatment of heart failure [18] and resistant hypertension [19], as well as albuminuria reduction, both in diabetic and non-diabetic CKD [20]. Here, NR3C2 is linked to chronic kidney disease.